I.CERAM 2023 annual results: a year marked by challenges

The I.CERAM board of directors, chaired by André Kérisit, met on June 6, 2024 to examine the accounts for the 2023 financial year. However, these accounts have not yet been finalized, due to the current drafting of the Universal Registration Document. The company is currently in receivership since April 24, 2024.

The 2023 turnover stood at €992,000, down 29.5% compared to 2022. The gross margin fell by 62.4%, including an inventory change of €340,000. As of December 31, 2023, shareholders' equity was €936 thousand and net financial debt amounted to €1.6 million, reduced to €1.2 million at the end of March 2024.

I.CERAM, specialized in implants loaded with antibiotics, continues its development despite this difficult period and aims to be a benchmark player in the treatment of sternal pathologies.